Screener
Inhibrx Biosciences, Inc. INBX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | MARCH 31, 2026 | DECEMBER 31, 2025 |
|---|---|---|
| Accrued expenses | 15,342 | 25,529 |
| Current portion of operating lease liability | 2,408 | 2,326 |
| Total current liabilities | 26,512 | 33,799 |
| Long-term debt, net | 174,994 | 100,559 |
| Non-current portion of operating lease liability | 3,496 | 4,127 |
| Total liabilities | 205,002 | 138,485 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity (deficit) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s long-term debt?
- Inhibrx Biosciences, Inc. (INBX) reported long-term debt of $174.99M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s long-term debt changed year-over-year?
- Inhibrx Biosciences, Inc.'s long-term debt increased by 77.4% year-over-year, from $98.65M to $174.99M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s long-term debt?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s long-term debt has grown at a -30.3% compound annual growth rate (CAGR), from $206.97M to $100.56M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Inhibrx Biosciences, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude